30 closest matches · ranked by relevance
B-cell Follicular Lymphoma · B-cell Marginal Zone Lymphoma · Diffuse Large B-cell Lymphoma
Primary: Number of Participants With Dose-Limiting Toxicity (DLT) — 1; 2; 0; 1 participants
Hematologic Malignancies
Primary: Retention Rate — 38; 3 Participants
Hematologic Malignancy
Primary: Overall Survival — 79; 49 Participants
Adult Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia · Therapy-Related Acute Myeloid Leukemia
Primary: Rate of Complete Remission and Mortality in the Entire Cohort of Older Patients — 21.9; 52.0 percentage of subjects
Acute Myeloid Leukemia · Lymphoblastic Leukemia · Acute Leukemia
Primary: Number of Participants With Grade 4 TMI Toxicity — 0; 0; 0; 2 Participants
Acute Myeloid Leukemia · Myeloid and Monocytic Leukemia · Myelodysplastic Syndromes
Primary: Efficacy of Combined Modality Treatment (Ruxolitinib, Decitabine, and DLI) for Relapsed AML or MDS Post Allo-HCT: Rate of Overall Survival (OS) — 36 Percentage of…
Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: Achievability of Performing Individualized Drug Screening and Initiating Therapy Based on the Results of the Drug Screen for Poor Risk Patients With Relapsed or…
Acute Myeloid Leukemia (AML) · Myelodysplastic Syndrome (MDS)
Primary: Percentage Analyzed Participants Receiving Hematopoietic Stem Cell Transplantation (HCT) — 44.7 % participants
Hematologic Malignancies
Primary: Number of Participants With Successful Bone Marrow Engraftment — 1; 15; 1 Participants
Leukemia · Lymphoma
Primary: Number of Participants With Absolute Neutrophil Count Engraftment — 21 participant
Acute Myelogenous Leukemia (AML) · Acute Lymphoblastic Leukemia (ALL) · Myelodysplastic Syndromes (MDS)
Primary: Number of Participants With Dose Limiting Toxicity (DLT) Events — 0; 0; 0; 0 Participants
Acute Myeloid Leukemia (AML)
Primary: Overall Survival (OS) — 9.6; 14.7 months — p=<0.001
Leukemia, Myeloid, Acute
Primary: Phase I Only: Optimal Dose of AMD3100 Plus MEC in Patients With Relapsed or Refractory AML — 240 mcg/kg
Hematological Malignancies
Primary: Overall Survival at 6 Months Post-transplant in Patients Receiving a Partially-matched Related Donor Allogeneic Transplant After Reduced-intensity Conditioning — 22…
Leukemia · Acute Lymphoblastic Leukemia
Primary: Number of Participants With a Response — 198; 3; 4 Participants
Leukemia, Myeloid, Acute · Leukemia, Lymphoblastic, Acute · Leukemia, Myelocytic, Chronic
Primary: Overall Recipient Survival at 6-month Post-relapse of Disease — 0; 4 participants
Advanced B-cell Lymphoid Malignancies
Primary: Total Number of Adverse Events. — 2 Adverse events
Acute Myelogenous Leukemia · High-Grade Myelodysplastic Syndrome
Primary: Best Overall Response Rate (ORR) Based on Investigator's Assessment — 6; 0; 1; 0 participants
Leukemia, Acute Lymphocytic (ALL) · Leukemia, Myeloid, Acute(AML) · Leukemia, Myeloid, Chronic(CML)
Primary: Event-free Survival (EFS) — 54.8 Percentage of participants
Advanced Haematological Malignancies
Primary: Module 1: Number of Participants With Adverse Events — 9; 28; 4; 16 Participants
Acute Myeloid Leukemia (AML) · Myelodysplastic Syndrome
Primary: Percentage of Participants With Objective Response (OR) — 0 Percentage of participants
Multiple Myeloma
Primary: Feasibility to Mobilize and Infuse Autologous Lymphocytes (ALI) After Immunomodulatory Therapy and After Stem Cell Transplant Engraftment — 17; 16; 1 participants
Hematopoietic and Lymphoid Cell Neoplasm
Primary: Number of Patients With Adverse Events (AE), Graded According to Common Terminology Criteria for Adverse Events Version 5.0 — 0 Participants
Sickle Cell Disease · Thalassemia · Diamond-Blackfan Anemia
Primary: Count of Participants With Stable Engraftment Post Hematopoietic Cell Transplantation (HCT) — 3 Participants
Multiple Myeloma, Relapsed · Multiple Myeloma, Refractory to Standard Treatment
Primary: Maximum Tolerated Dose (MTD) of Gy — NA Participants
Lymphoma · Leukemia · Multiple Myeloma
Primary: Number of Participants DLT in Arm 1 in Dose Escalation Phase — 0; 0; 2; 1 Participants
Multiple Myeloma
Primary: Percentage of Patients With MRD(-) Remissions at the Completion of Consolidation Therapy — 81.4 percentage of patients achieving MRD (-)
Acute Myelogenous Leukemia
Primary: < 5% Marrow Blast, no Circulating Peripheral Blasts and Neutrophil Count of > 1 x 10^9/L — 5 Participants
Acute Myeloid Leukemia
Primary: Number of Participants That Achieved Complete Remission — 20 Participants
Novo Acute Myeloid Leukemia
Primary: Complete Remission of the Disease — NA; 18; 16; NA Participants